about
Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression dataTarget prediction for an open access set of compounds active against Mycobacterium tuberculosisHIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencingRelease of 50 new, drug-like compounds and their computational target predictions for open source anti-tubercular drug discoverySelective Spectrum Antibiotic Modulation of the Gut Microbiome in Obesity and Diabetes Rodent ModelsNew compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase.Comparative genomics of Klebsiella pneumoniae strains with different antibiotic resistance profiles.Human microbial metabolites as a source of new drugs.Computational biology in anti-tuberculosis drug discovery.Modulating the human gut microbiome as an emerging therapeutic paradigm.Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.Sputum microbiome temporal variability and dysbiosis in chronic obstructive pulmonary disease exacerbations: an analysis of the COPDMAP study.Minipig and beagle animal model genomes aid species selection in pharmaceutical discovery and development.Meta-analysis of human gene expression in response to Mycobacterium tuberculosis infection reveals potential therapeutic targets.Shared Molecular Signatures Across Neurodegenerative Diseases and Herpes Virus Infections Highlights Potential Mechanisms for Maladaptive Innate Immune Responses.Airway host-microbiome interactions in chronic obstructive pulmonary disease.The Microbiome Factor in Drug Discovery and DevelopmentObesity and disease severity magnify disturbed microbiome-immune interactions in asthma patientsGut microbiome differences between metformin- and liraglutide-treated T2DM subjectsT Cell- and Monocyte-Specific RNA-Sequencing Analysis in Septic and Nonseptic Critically Ill Patients and in Patients with CancerMicrobiome Metabolite Mimics Accelerate Drug DiscoveryPICRUSt2 for prediction of metagenome functions
P50
Q28533874-3488FC78-C15F-4FDC-84C8-9D016EFA015EQ28534065-02EBD0F0-1CED-4017-864A-C739703B5A1CQ28540159-61BF3245-68B5-487B-BB7F-325004435654Q28551386-E4367036-1606-44D8-BB5C-AF1010DF4A95Q28551809-0E6F5CCE-E97B-4A10-80E0-F63488390934Q30417002-98B1EAEE-4F59-4892-922E-2AC9907546E4Q33838229-A0F5418D-B711-47F2-AB03-2B58CD6CA3E8Q34922438-94662C43-4A9B-408A-8B06-84DF472CF859Q35105814-74B81D31-3729-4E37-A9C6-A134594DCB6DQ35191608-645D35E4-3039-4B8D-B6A1-6DB8C196B89CQ35936307-A40B746D-D1C9-46A3-838F-409F5B3F28F9Q37516043-26D762E5-5F8B-4F20-AA6A-633382ACB2EAQ38163549-205D1988-71ED-4036-8EA1-BC91584E558DQ47547470-E0F676B2-F0A5-49B3-84B9-714CA4EBB956Q47672817-877E2D3F-0C0C-43CC-AA42-435D2CC1735EQ48039754-16602D0E-A3AA-4F87-907E-58AA39500A2CQ49807763-A9F153F5-DFA1-4392-9DB7-3FB7EAEF136BQ64929938-9796DCD4-7B46-47B4-BF6F-E717F28A318FQ64962056-2A6B754D-6136-486E-800B-BA5BF1F574E3Q91704066-24CB6447-25AB-41D9-8F9C-F0AA5BFEE4F3Q91972842-8B7AC83F-1021-487B-8A0B-179A17D86ABAQ91991851-CBD29D16-AE75-480F-993E-BF8472AF38F2Q93104948-083A4F04-4564-495D-9764-B596E7CF52D4Q94487334-AC8F9E5D-3CA1-42A9-B700-97DC91DC6F8FQ96127736-276C9022-25B2-4FC2-852D-AC469D62A269
P50
description
researcher ORCID ID = 0000-0002-9368-627X
@en
wetenschapper
@nl
name
James R Brown
@ast
James R Brown
@en
James R Brown
@nl
type
label
James R Brown
@ast
James R Brown
@en
James R Brown
@nl
prefLabel
James R Brown
@ast
James R Brown
@en
James R Brown
@nl
P31
P496
0000-0002-9368-627X